Compares upadacitinib with corticosteroids for severe ulcerative colitis flares
Tests upadacitinib against corticosteroids as first treatment in adults with severe ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）
Key facts
- Where
- Ankang, Hanzhong, Xi'an, and Xianyang, ChinaSee the 4 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute severe ulcerative colitis. It compares upadacitinib with corticosteroids as the first treatment.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Acute severe ulcerative colitis (ASUC)
Main reasons for not taking part
- Allergy, intolerance or a reason not to take upadacitinib or glucocorticoids
- Needs immediate removal of the colon (colectomy)
- Crohn's disease, confirmed gut infection, unstable blood circulation, or clinically significant cytomegalovirus infection
- Current cancer, or severe long-term disease of the heart, lungs, liver, kidneys, blood or other organs
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07546097, who can take part
Where in China
- Ankang Central HospitalAnkang, ChinaTaking people
- 3201 HospitalHanzhong, ChinaTaking people
- Xijing hospitalXi'an, ChinaTaking people
- Shaanxi Provincial Nuclear Industry 215 HospitalXianyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yongquan Shi
- Trial code
- NCT07546097
- Record updated
- 15 June 2026
- Original description
The goal of this clinical trial is to learn comparative effectiveness and safety of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis. The main questions it aims to answer are:Read full original descriptionShow less
Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis: Multicenter, Open-label, Non-inferiority, Randomized Controlled Study
The goal of this clinical trial is to learn comparative effectiveness and safety of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis. The main questions it aims to answer are:
1. Whether upadacitinib can effectively induce remission in acute severe ulcerative colitis with an efficacy non-inferior to that of corticosteroids. 2. What adverse reactions may occur with upadacitinib in the treatment of acute severe ulcerative colitis?
Researchers will compare upadacitinib with corticosteroids to evaluate the efficacy of upadacitinib in the treatment of acute severe ulcerative colitis.Participants will:
1. Upadacitinib group: Upadacitinib extended-release tablets 45 mg once daily for 8 weeks, then adjusted to 30 mg once daily. 2. Corticosteroid group: Methylprednisolone for injection 60 mg/day. If clinical response is achieved, switch to oral prednisone acetate tablets after 5 days (calculated at 0.75 mg/kg/day), followed by a weekly prednisone taper of 5 mg. When the dose is reduced to 20 mg, taper by 2.5 mg weekly until discontinued, with mesalazine 4 g/day as maintenance therapy. 3. Take drug Upadacitinib or Corticosteroid every day for 3 months 4. Visit the clinic once every 2 weeks for checkups and tests 5. Record the patient's bowel movements and the presence of symptoms such as abdominal pain, while performing colonoscopy, ultrasound examination, and blood tests at the specified time points.
Inclusion: Patients diagnosed with ASUC; Aged 18 years or older; No gender restriction.
Exclusion: Presence of contraindications, allergy, or intolerance to upadacitinib or glucocorticoids; Patients requiring immediate colectomy; diagnosis of Crohn's disease; confirmed intestinal infection; hemodynamic instability; clinically significant cytomegalovirus infection; current malignancy; Presence of severe underlying systemic diseases involving the heart, lungs, liver, kidneys, hematologic system, or other organ systems; Pregnant or breastfeeding women; Unwilling to participate in the clinical study.